Nacuity Pharmaceuticals, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$8M
Investors
98
Min Invest
$9,375
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Nacuity Pharmaceuticals, Inc. is a Delaware corporation that first filed a Form D on December 8, 2016 and most recently amended it on December 30, 2025 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity and debt. Nacuity Pharmaceuticals, Inc. reported $8,393,350 sold from 98 investors of a $30,000,000 total offering as of the Form D filed December 30, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $9,375. The Form D names Maxim Group LLC (CRD 120708), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $839,335 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is Fort Worth Club Bldg., 306 W. 7th Street, Suite 310, Fort Worth, TX 76102.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Dec 30, 2025
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
lapsed, raising
Latest event New filer · Dec 30, 2025
SEC.govInvestor
- 1 filing event with values and deltas, latest 2025-12-30, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2025-12-30: 5 related persons added and 2 removed against the filing of 2022-01-03; 10 now listed. The names are in the Terminal feed.
Halden Conner
Executive Officer, Director · Fort Worth, TX
David Wohlberg
Executive Officer, Director · Fort Worth, TX
Gerald Cagle
Director · Fort Worth, TX
Emmett Cunningham, Jr.
Director · Fort Worth, TX
Rusty Kelley
Director · Fort Worth, TX
Robin Steele
Director · Fort Worth, TX
Benjamin Yerxa
Director · Fort Worth, TX
Jami Kern
Executive Officer · Fort Worth, TX
Charles Lieser
Executive Officer · Fort Worth, TX
Michael Wall
Executive Officer · Fort Worth, TX
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Maxim Group LLCCRD 120708 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states and outside the United States
Questions About Nacuity Pharmaceuticals, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Nacuity Pharmaceuticals, Inc.?
Nacuity Pharmaceuticals, Inc. is a Delaware corporation that filed a Form D with the SEC on December 30, 2025 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity and debt.
Is Nacuity Pharmaceuticals, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Nacuity Pharmaceuticals, Inc. filed a Form D with the SEC on December 30, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $8,393,350 sold to 98 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Nacuity Pharmaceuticals, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Nacuity Pharmaceuticals, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Nacuity Pharmaceuticals, Inc. raised?
Nacuity Pharmaceuticals, Inc. reported $8,393,350 sold from 98 investors of a $30,000,000 total offering as of the Form D filed December 30, 2025.
Who can invest in Nacuity Pharmaceuticals, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $9,375.
What is the minimum investment in Nacuity Pharmaceuticals, Inc.?
The Form D lists $9,375 as the minimum investment accepted from any outside investor as of December 30, 2025. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Nacuity Pharmaceuticals, Inc. and how are they paid?
The Form D names Maxim Group LLC (CRD 120708), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $839,335 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Nacuity Pharmaceuticals, Inc.?
The Form D lists 10 related persons: Halden Conner, executive officer, director; David Wohlberg, executive officer, director; Gerald Cagle, director; Emmett Cunningham, Jr., director; Rusty Kelley, director; Robin Steele, director; Benjamin Yerxa, director; Jami Kern, executive officer, and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Nacuity Pharmaceuticals, Inc. located?
The issuer's address on its SEC filings is Fort Worth Club Bldg., 306 W. 7th Street, Suite 310, Fort Worth, TX 76102. Its phone number of record is 817-336-3000. It is organized under the laws of Delaware.
How long is the Nacuity Pharmaceuticals, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.
What is Nacuity Pharmaceuticals, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
